Cure Genetics and Frametact Strike $60M Deal for Familial Neurological Disease Gene Therapy

15 September 2023 | Friday | News

Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement.
Image Source : Public Domain

Image Source : Public Domain

The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases. According to the agreement, Cure Genetics will receive an upfront and milestone payment totaling $60 million. Additionally, upon the market launch of the product, Cure Genetics will continue to receive sales royalties based on net revenue.

This collaboration will leverage the extensive expertise of Frametact in the domain of neurological diseases, combined with Cure Genetics' leading technology in AAV vector development and efficient in vivo AAV screening. Together, the companies will work on developing treatments for familial neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease.

This collaboration, following a previous partnership with Boehringer Ingelheim, marks another significant step forward for Cure Genetics with a globally leading organization. It not only validates the global advancement of the VELP™ platform but also signifies a leap forward in Cure Genetics' internationalization process. Cure Genetics looks forward to working with Frametact to accelerate the development of gene therapy products for brain diseases.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in